# Ipsen Bids Up to $1.75 Billion for Memo Therapeutics and Its Potravitug Asset

> ma · REPORTED · 2026-07-03

French drugmaker Ipsen announced a bid of up to $1.75 billion to acquire Memo Therapeutics and its lead asset potravitug, coming shortly after the company also announced a separate $450 million deal to acquire Kartos Therapeutics. The back-to-back acquisitions signal aggressive pipeline expansion by Ipsen in oncology and beyond.

About Ipsen: Ipsen is a France-based global specialty pharmaceutical company focused on oncology, rare disease, and neuroscience, pursuing growth through late-stage pipeline acquisitions and licensing.

- Company: Ipsen
- Sector: therapeutics
- Primary source: https://www.thepharmaletter.com/biotech-news/the-week-in-pharma-action-reaction-and-insight-week-to-july-3-2026

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.